Established and novel treatment options in acute myocarditis, with or without heart failure

References

• Caforio AL, Pankuweit S, Arbustini E, et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European society of cardiology working group on myocardial and pericardial diseases. Eur Heart J. 2013;34:2636–2648.
   PubMed Web of Science ®Google Scholar
• Liu PP, Schultheiss HP. Myocarditis. In: Braunwald, Editor. Heart Disease. Philadelphia: W B Saunders Co.; 2008. p. 1775–1792.
   Google Scholar
• Pinto YM, Elliott PM, Arbustini E, et al. Proposal for a revised definition of dilated cardiomyopathy, hypokinetic non-dilated cardiomyopathy, and its implications for clinical practice: a position statement of the ESC working group on myocardial and pericardial diseases. Eur Heart J. 2016;37:1850–1858.
   PubMed Web of Science ®Google Scholar
• Adler Y, Charron P, Imazio M, et al. ESC guidelines for the diagnosis and management of pericardial diseases: the task force for the diagnosis and management of pericardial diseases of the European Society of Cardiology (ESC). Eur Heart J. 2015;36:2921–2964.
   PubMed Web of Science ®Google Scholar
• Sagar S, Liu PP, Cooper LT Jr. Myocarditis. Lancet. 2012;379:738–747.
   PubMed Web of Science ®Google Scholar
• Shauer A, Gotsman I, Keren A, et al. Acute viral myocarditis: current concepts in diagnosis and treatment. Isr Med Assoc J. 2013;15:180–185.
   PubMed Web of Science ®Google Scholar
• Monti L, Moro C, Occhi L, et al. Beta blockers for haemodynamically stable acute myocarditis. J Cardiovasc Magn Reson. 2014;16(Suppl 1):P277.
   Google Scholar
• Kindermann I, Barth C, Mahfoud F, et al. Update on myocarditis. J Am Coll Cardiol. 2012;59:779–792.
   PubMed Web of Science ®Google Scholar
• Mirabel M, Luyt CE, Leprince P, et al. Outcomes, long-term quality of life, and psychologic assessment of fulminant myocarditis patients rescued by mechanical circulatory support. Crit Care Med. 2011;39:1029–1035.
   PubMed Web of Science ®Google Scholar
• Chen YS, Wang MJ, Chou NK, et al. Rescue for acute myocarditis with shock by extracorporeal membrane oxygenation. Ann Thorac Surg. 1999;68:2220–2224.
   PubMed Web of Science ®Google Scholar
• Hsu KH, Chi NH, Yu HY, et al. Extracorporeal membranous oxygenation support for acute fulminant myocarditis: analysis of a single center’s experience. Eur J Cardiothorac Surg. 2011;40:682–688.
   PubMed Web of Science ®Google Scholar
• McNamara DM, Holubkov R, Starling RC, et al. Controlled trial of intravenous immune globulin in recent-onset dilated cardiomyopathy. Circulation. 2001;103:2254–2259.
   PubMed Web of Science ®Google Scholar
• Cooper L. Myocarditis. N Engl J Med. 2009;360(1526–1538):1526–1538.
   PubMed Web of Science ®Google Scholar
• McCarthy RE, Boehmer JP, Hruban RH, et al. Long-term outcome of fulminant myocarditis as compared with acute (non fulminant) myocarditis. N Engl J Med. 2000;342:690–695.
   PubMed Web of Science ®Google Scholar
• Cooper LT Jr, Berry GJ, Shabetai R. Idiopathic giant-cell myocarditis–natural history and treatment. Multicenter giant cell myocarditis study group investigators. N Engl J Med. 1997;336:1860–1866.
   PubMed Web of Science ®Google Scholar
• Gupta S, Markham DW, Drazner MH, et al. Fulminant myocarditis. Nat Clin Pract Cardiovasc Med. 2008;5:693–706.
   PubMedGoogle Scholar
• Cooper LT, Baughman KL, Feldman AM, et al. The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American heart association, the American college of cardiology, and the European society of cardiology. Circulation. 2007;116:2216–2233.
   PubMed Web of Science ®Google Scholar
• Li H, Dai Z, Wang B, et al. A case report of eosinophilic myocarditis and a review of the relevant literature. BMC Cardiovasc Disord. 2015;15:15.
   PubMed Web of Science ®Google Scholar
• Gkouziouta A, Miliopoulos D, Karavolias G, et al. Acute cytomegalovirus infection triggering fatal giant cell myocarditis. Int J Cardiol. 2016;214:204–206.
   PubMed Web of Science ®Google Scholar
• Ekström K, Lehtonen J, Kandolin R, et al. Long-term outcome and its predictors in giant cell myocarditis. Eur J Heart Fail. 2016 Jul;13. DOI:10.1002/ejhf.606,
   Google Scholar
• Kandolin R, Lehtonen J, Salmenkivi K, et al. Diagnosis, treatment, and outcome of giant-cell myocarditis in the era of combined immunosuppression. Circ Heart Fail. 2013;6:15–22.
   PubMed Web of Science ®Google Scholar
• Menghini VV, Savcenko V, Olson LJ, et al. Combined immunosuppression for the treatment of idiopathic giant cell myocarditis. Mayo Clin Proc. 1999;74:1221–1226.
   PubMed Web of Science ®Google Scholar
• Ponikowski P, Voors AA, Anker SD, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European society of cardiology. Eur Heart J. 2016;2016(37):2129–2200.
   Web of Science ®Google Scholar
• Writing committee members; ACC/AHA TASK FORCE members. 2016. ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. J Card Fail. 2016;22:659-669.
   Web of Science ®Google Scholar
• Veeraveedu PT, Watanabe K, Ma M, et al. Torasemide, a long acting loop diuretic, reduces the progression of myocarditis to dilated cardiomyopathy. Eur J Pharmacol. 2008;581:121–131.
   PubMed Web of Science ®Google Scholar
• Kindermann I, Kindermann M, Kandolf R, et al. Predictors of outcome in patients with suspected myocarditis. Circulation. 2008;118:639–648.
   PubMed Web of Science ®Google Scholar
• Feldman AM, McNamara D. Myocarditis. N Engl J Med. 2000;343(1388–1398):1388–1398.
   PubMed Web of Science ®Google Scholar
• Tominaga M, Matsumori A, Okada I, et al. Beta-blocker treatment of dilated cardiomyopathy: beneficial effect of carteolol in mice. Circulation. 1991;83:2021–2028.
   PubMed Web of Science ®Google Scholar
• Yuan Z, Shioji K, Kihara Y, et al. Cardioprotective effects of carvedilol on acute autoimmune myocarditis: anti-inflammatory effects associated with antioxidant property. Am J Physiol Heart Circ Physiol. 2004;286:H83–H90.
   PubMed Web of Science ®Google Scholar
• Rezkalla S, Kloner RA, Khatib G, et al. Effect of metoprolol in acute coxsackievirus B3 murine myocarditis. J Am Coll Cardiol. 1988;12:412–414.
   PubMed Web of Science ®Google Scholar
• Saegusa S, Fei Y, Takahashi T, et al. Oral administration of candesartan improves the survival of mice with viral myocarditis through modification of cardiac adiponectin expression. Cardiovasc Drugs Ther. 2007;21:155–160.
   PubMed Web of Science ®Google Scholar
• Bahk TJ, Daniels MD, Leon JS, et al. Comparison of angiotensin converting enzyme inhibition and angiotensin II receptor blockade for the prevention of experimental autoimmune myocarditis. Int J Cardiol. 2008;125:85–93.
   PubMed Web of Science ®Google Scholar
• Sukumaran V, Watanabe K, Veeraveedu PT, et al. Beneficial effects of olmesartan, an angiotensin II receptor type 1 antagonist, in rats with dilated cardiomyopathy. Exp Biol Med. (Maywood). 2010;235:1338–1346.
   PubMed Web of Science ®Google Scholar
• Reyes MP, Khatib R, Khatib G, et al. Prolonged captopril therapy in murine viral myocarditis. J Cardiovasc Pharmacol Ther. 1998;3:43–50.
   PubMedGoogle Scholar
• Seko Y. Effect of the angiotensin II receptor blocker olmesartan on the development of murine acute myocarditis caused by coxsackievirus B3. Clin Sci (Lond). 2006;110:379–386.
   PubMed Web of Science ®Google Scholar
• Araki M, Kanda T, Imai S, et al. Comparative effects of losartan, captopril, and enalapril on murine acute myocarditis due to encephalomyocarditis virus. J Cardiovasc Pharmacol. 1995;26:61–65.
   PubMed Web of Science ®Google Scholar
• Xiao J, Shimada M, Liu W, et al. Antiinflammatory effects of eplerenone on viral myocarditis. Eur J Heart Fail. 2009;11:349–353.
   PubMed Web of Science ®Google Scholar
• Anguita-Sánchez M, Castillo-Domínguez JC, Mesa-Rubio D, et al. Should angiotensin-converting enzyme inhibitors be continued over the long term in patients whose left ventricular ejection fraction normalizes after an episode of acute myocarditis? Rev Esp Cardiol. 2006;59:1199–1201.
   PubMed Web of Science ®Google Scholar
• Dennert R, Crijns HJ, Heymans S. Acute viral myocarditis. Eur Heart J. 2008;29:2073–2082.
   PubMed Web of Science ®Google Scholar
• Karavidas A, Lazaros G, Noutsias M, et al. Recurrent coxsackie B viral myocarditis leading to progressive impairment of left ventricular function over 8 years. Int J Cardiol. 2011;151:e65–e7.
   PubMed Web of Science ®Google Scholar
• Veeraveedu PT, Watanabe K, Ma M, et al. Comparative effects of pranidipine with amlodipine in rats with heart failure. Pharmacology. 2006;77:1–10.
   PubMed Web of Science ®Google Scholar
• Liu W, Shimada M, Xiao J, et al. Nifedipine inhibits the activation of inflammatory and immune reactions in viral myocarditis. Life Sci. 2009;85:235–240.
   PubMed Web of Science ®Google Scholar
• Canter CE, Simpson KE. Diagnosis and treatment of myocarditis in children in the current era. Circulation. 2014;129:115–128.
   PubMed Web of Science ®Google Scholar
• Matsumori A, Igata H, Ono K, et al. High doses of digitalis increase the myocardial production of proinflammatory cytokines and worsen myocardial injury in viral myocarditis: a possible mechanism of digitalis toxicity. Jpn Circ J. 1999;63:934–940.
   PubMedGoogle Scholar
• Costanzo-Nordin MR, Reap EA, O’Connell JB, et al. A non-steroidal anti-inflammatory drug exacerbates coxsackie B3 murine myocarditis. J Am Coll Cardiol. 1985;6:1078–1082.
   PubMed Web of Science ®Google Scholar
• Khatib R, Reyes MP, Smith F, et al. Enhancement of coxsackievirus B4 virulence by indomethacin. J Lab Clin Med. 1990;116:116–120.
   PubMed Web of Science ®Google Scholar
• Khatib R, Reyes MP, Smith FE. Enhancement of coxsackievirus B3 replication in vero cells by indomethacin. J Infect Dis. 1990;162:997–998.
   PubMed Web of Science ®Google Scholar
• Blauwet LA, Cooper LT. Myocarditis. Prog Cardiovasc Dis. 2010;52:274–288.
   PubMed Web of Science ®Google Scholar
• Friedrich MG, Sechtem U, Schulz-Menger J, et al. International consensus group on cardiovascular magnetic resonance in myocarditis. Cardiovascular magnetic resonance in myocarditis: a JACC white paper. J Am Coll Cardiol. 2009;53:1475–1487.
   PubMed Web of Science ®Google Scholar
• Imazio M, Brucato A, Barbieri A, et al. Good prognosis for pericarditis with and without myocardial involvement: results from a multicenter, prospective cohort study. Circulation. 2013;128:42–49.
   PubMed Web of Science ®Google Scholar
• Imazio M, Cooper LT. Management of myopericarditis. Expert Rev Cardiovasc Ther. 2013;11:193–201.
   PubMedGoogle Scholar
• Imazio M, Brucato A, Forno D, et al. Efficacy and safety of colchicine for pericarditis prevention. Systematic review and meta-analysis. Heart. 2012;98:1078–1082.
   PubMed Web of Science ®Google Scholar
• Dubrey SW, Falk RH. Diagnosis and management of cardiac sarcoidosis. Prog Cardiovasc Dis. 2010;52:336–346.
   PubMed Web of Science ®Google Scholar
• Priori SG, Blomström-Lundqvist C, Mazzanti A, et al. ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur Heart J. 2015;2015(36):2793–2867.
   Google Scholar
• Aziz S, Leon AR, El-Chami MF. The subcutaneous defibrillator: a review of the literature. J Am Coll Cardiol. 2014;63:1473–1479.
   PubMed Web of Science ®Google Scholar
• Ali H, Lupo P, Cappato R. The entirely subcutaneous defibrillator - A new generation and future expectations. Arrhythm Electrophysiol Rev. 2015;4:116–121.
   PubMedGoogle Scholar
• Mason JW, O Connell JB, Herskowitz A, et al. A clinical trial of immunosuppressive therapy for myocarditis. N Engl J Med. 1995;333:269–275.
   PubMed Web of Science ®Google Scholar
• Frustaci A, Russo MA, Chimenti C. Randomized study on the efficacy of immunosuppressive therapy in patients with virus-negative inflammatory cardiomyopathy: the TIMIC study. Eur Heart J. 2009;30:1995–2002.
   PubMed Web of Science ®Google Scholar
• Adamopoulos S, Gkouziouta A, Lazaros G, et al. Endomyocardial biopsy in new onset dilated cardiomyopathy: prevalence and prognostic role of infectious agents. Int J Cardiol. 2013;168:e129–e30.
   PubMed Web of Science ®Google Scholar
• Wojnicz R, Nowalany-Kozielska E, Wojciechowska C, et al. Randomized, placebo-controlled study for immunosuppressive treatment of inflammatory dilated cardiomyopathy: two-year follow-up results. Circulation. 2001;104:39–45.
   PubMed Web of Science ®Google Scholar
• Caforio AL, Calabrese F, Angelini A, et al. A prospective study of biopsy-proven myocarditis: prognostic relevance of clinical and aetiopathogenetic features at diagnosis. Eur Heart J. 2007;28:1326–1333.
   PubMed Web of Science ®Google Scholar
• Pollack A, Kontorovich AR, Fuster V, et al. Viral myocarditis–diagnosis, treatment options, and current controversies. Nat Rev Cardiol. 2015;12:670–680.
   PubMed Web of Science ®Google Scholar
• Gkouziouta A, Lazaros G, Karavidas A, et al. Pathogen-driven treatment strategy in new onset dilated cardiomyopathy. Impact on ventricular function and clinical outcome. Int J Cardiol. 2016;209:15–16.
   PubMed Web of Science ®Google Scholar
• Schultheiss HP, Kuhl U, Cooper LT. The management of myocarditis. Eur Heart J. 2011;32:2616–2625.
   PubMed Web of Science ®Google Scholar
• Mavrogeni S, Markousis-Mavrogenis G, Kolovou G. How to approach the great mimic? Improving techniques for the diagnosis of myocarditis. Expert Rev Cardiovasc Ther. 2016;14:105–115.
   PubMed Web of Science ®Google Scholar
• Kuhl U, Pauschinger M, Schwimmbeck PL, et al. Interferon beta treatment eliminates cardiotropic viruses and improves left ventricular function in patients with myocardial persistence of viral genomes and left ventricular dysfunction. Circulation. 2003;107:2793–2798.
   PubMed Web of Science ®Google Scholar
• Schultheiss HP, Piper C, Sowade K, et al. The effect of subcutaneous treatment with interferon-beta-1b over 24 weeks on safety, virus elimination and clinical outcome in patients with chronic viral cardiomyopathy (abstr). Circulation. 2008;118:3322.
   Google Scholar
• Imazio M, Lazaros G, Brucato A, et al. Recurrent pericarditis: new and emerging therapeutic options. Nat Rev Cardiol. 2016;13:99–105.
   PubMed Web of Science ®Google Scholar
• Robinson J, Hartling L, Vandermeer B, et al. Intravenous immunoglobulin for presumed viral myocarditis in children and adults. Cochrane Database Syst Rev. 2015 May 20; (5):CD004370. doi: 10.1002/14651858.
   Web of Science ®Google Scholar
• Drucker NA, Colan SD, Lewis AB, et al. Gamma-globulin treatment of acute myocarditis in the pediatric population. Circulation. 1994;89:252–257.
   PubMed Web of Science ®Google Scholar
• Di Filippo S. Improving outcomes of acute myocarditis in children. Expert Rev Cardiovasc Ther. 2016;14:117–125.
   PubMed Web of Science ®Google Scholar
• Felix SB, Beug D, Dörr M. Immunoadsorption therapy in dilated cardiomyopathy. Expert Rev Cardiovasc Ther. 2015;13:145–152.
   PubMed Web of Science ®Google Scholar
• Lazaros G, Karavidas A, Spyropoulou M, et al. The role of the immunogenetic background in the development and recurrence of acute idiopathic pericarditis. Cardiology. 2011;118:55–62.
   PubMed Web of Science ®Google Scholar
• Huber SA. Autoimmunity in myocarditis: relevance of animal models. Clin Immunol Immunopathol. 1997;83:93–102.
   PubMedGoogle Scholar
• Matsumori A. Emerging treatments for viral myocarditis. Future Cardiol. 2005;1:683–692.
   PubMedGoogle Scholar
• Coronado MJ, Brand JE, Kim E, et al. Testosterone and interleukin-1β increase cardiac remodeling during coxsackievirus B3 myocarditis via serpin A 3n. Am J Physiol Circ Physiol. 2012;302:H1726–H1736.
   PubMed Web of Science ®Google Scholar
• Jensen LD, Marchant DJ. Emerging pharmacologic targets and treatments for myocarditis. Pharmacol Ther. 2016;161:40–51.
   PubMed Web of Science ®Google Scholar
• Nugent AW, Daubeney PE, Chondros P, et al. National Australian childhood cardiomyopathy study. The epidemiology of childhood cardiomyopathy in Australia. N Engl J Med. 2003;348:1639–1646.
   PubMed Web of Science ®Google Scholar
• Corsten N, Papageorgiou A, Verhesen W, et al. MicroRNA profiling identifies microRNA-155 as an adverse mediator of cardiac injury and dysfunction during acute viral myocarditis. Circ Res. 2012;111:415–425.
   PubMed Web of Science ®Google Scholar
• Magnani J, Dec W. Myocarditis: Current Trends in Diagnosis and Treatment Circulation. 2006;113:876–890.
   Google Scholar
• Mahrholdt H, Wagner A, Deluigi CC, et al. Presentation, patterns of myocardial damage and clinical course of viral myocarditis. Circulation. 2006;114:1581–1590.
   PubMed Web of Science ®Google Scholar
• Cooper LT. The natural history and role of immunoadsorption in dilated cardiomyopathy. J Clin Apher. 2005;20:256–260.
   PubMed Web of Science ®Google Scholar
• Liu P, Mason J. Advances in the understanding of myocarditis. Circulation. 2001;104:1076–1082.
   PubMed Web of Science ®Google Scholar
• Basso C, Carturan E, Corrado D, et al. Myocarditis and dilated cardiomyopathy in athletes: diagnosis, management and recommendations for sport activity. Cardiol Clin. 2007;25:423–429.
   PubMed Web of Science ®Google Scholar
• Pelliccia A, Fagard R, Bjørnstad HH, et al. Recommendations for competitive sports participation in athletes with cardiovascular disease: a consensus document from the study group of sports cardiology of the working group of cardiac rehabilitation and exercise physiology and the working group of myocardial and pericardial diseases of the European society of cardiology. Eur Heart J. 2005;26:1422–1445.
   PubMed Web of Science ®Google Scholar